Zalicus Pharmaceuticals, Ltd.

Other

Mark G. Degiacomo, Interim Trustee

Degiacomo, Interim Trustee, Mark G.

Praxis Precision Medicines, Inc.

Taro Pharmaceuticals Inc.

Lingyun Zhang

Hassan Pajouhesh

Yuanxi Zhou

Nagasree Chakka

Yongbao Zhu

Yanbing Ding

Hossein Pajouhesh

Ramesh Kaul

Richard James Holland

Brendan Whelan

Jason Tan

Jason Lamontagne

Mike Grimwood

Michael Edward Grimwood

Brendan Whelen

The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) and in particular Formula (X), and Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions. 

Benzimidazole inhibitors of the sodium channel

The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns heterocyclic compounds (e.g., compounds according to any of Formulas (I)-(X) or Compounds (1)-(92) of Table 1) that are that are useful in treatment of conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotrophic lateral sclerosis, glaucoma, ischemia, spasticity disorders, obsessive compulsive disorder, restless leg syndrome and Tourette syndrome.

Heterocyclic inhibitors of the sodium channel

The invention relates to compounds useful in treating conditions associated with voltage-gated ion channel function, particularly conditions associated with sodium channel activity. More specifically, the invention concerns compounds (e.g., compounds according to any of Formulas (I)-(XIII) or Compounds (1)-(236) of Table 1) that are useful in treatment of a variety of diseases and conditions. 

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1). 

N-piperidinyl acetamide derivatives as calcium channel blockers

Growing community of inventors

Vancouver, Canada

Lingyun Zhang